Dr. Mulye and Nostrum, a drugmaker located in Missouri and New Jersey, admitted to increasing the price of an urinary tract infection drug more than 400% after changing amounts of two inactive pharmaceutical ingredients, the Justice Department said Oct. 30.
The tweaked recipe was marketed as a “reformulation” and the price of the drug, nitrofurantoin oral suspension, increased from $474.75 to $2,392.32 per bottle in 2018. This “triggered significantly higher Medicaid Drug Rebate invoices from State Medicaid programs,” and Nostrum and Dr. Mulye did not pay the entire invoiced amounts, the Justice Department said.
There was not a legal decision on liability because the case was settled.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
